
Metagenomi Therapeutics, Inc.: updates and filings
Price
$0.63
November 19, 2026Market cap $24M
What Ploutos Investor adds for Metagenomi Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 3 fiscal years, from 2023
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 10, 2026next Feb 10, 2027
A rough estimate from when it has reported before, which has varied. The company announces the date itself.
November 2026
August 2026
May 2026
March 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Regulation FD disclosureForm8-K
- Nov 10, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 10, 2026Results of operationsForm8-K
- Sep 22, 2026Regulation FD disclosureForm8-K
- Sep 10, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Aug 10, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 10, 2026Results of operationsForm8-K
- Jun 10, 2026Officer or director change, shareholder voteForm8-K
- May 11, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 11, 2026Results of operations, Regulation FD disclosureForm8-K
- Apr 27, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 27, 2026Additional annual meeting materialFormDEFA14A
- Apr 27, 2026Annual meeting proxy statementFormDEF 14A
- Mar 5, 2026Shares registered for employeesFormS-8
- Mar 5, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Mar 5, 2026Results of operationsForm8-K
- Jan 12, 2026Amended articles or bylaws, Regulation FD disclosureForm8-K
- Nov 12, 2025Quarterly reportfor the period to Sep 30, 2025Form10-Q
- Nov 12, 2025Results of operations, Regulation FD disclosureForm8-K
- Oct 1, 2025Material agreement entered, material agreement endedForm8-K
- Aug 12, 2025Quarterly reportfor the period to Jun 30, 2025Form10-Q
- Aug 12, 2025Results of operations, Regulation FD disclosureForm8-K
- Jun 11, 2025Shareholder voteForm8-K
- May 14, 2025Other material eventsForm8-K
- May 13, 2025Quarterly reportfor the period to Mar 31, 2025Form10-Q
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | 8-K | Regulation FD disclosure | Document |
| Nov 10, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 10, 2026 | 8-K | Results of operations | Document |
| Sep 22, 2026 | 8-K | Regulation FD disclosure | Document |
| Sep 10, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Aug 10, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 10, 2026 | 8-K | Results of operations | Document |
| Jun 10, 2026 | 8-K | Officer or director change, shareholder vote | Document |
| May 11, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 11, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Apr 27, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 27, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 27, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Mar 5, 2026 | S-8 | Shares registered for employees | Document |
| Mar 5, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Mar 5, 2026 | 8-K | Results of operations | Document |
| Jan 12, 2026 | 8-K | Amended articles or bylaws, Regulation FD disclosure | Document |
| Nov 12, 2025 | 10-Q | Quarterly reportfor the period to Sep 30, 2025 | Document |
| Nov 12, 2025 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Oct 1, 2025 | 8-K | Material agreement entered, material agreement ended | Document |
| Aug 12, 2025 | 10-Q | Quarterly reportfor the period to Jun 30, 2025 | Document |
| Aug 12, 2025 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Jun 11, 2025 | 8-K | Shareholder vote | Document |
| May 14, 2025 | 8-K | Other material events | Document |
| May 13, 2025 | 10-Q | Quarterly reportfor the period to Mar 31, 2025 | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Aug 16, 2019.
The full analysis
What do Metagenomi Therapeutics's filings show?
The filings are where every one of Metagenomi Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.